Mortality during the study
| . | Placebo, n = 28 . | Maribavir dose groups . | ||
|---|---|---|---|---|
| 100 mg twice daily, n = 28 . | 400 mg once daily, n = 28 . | 400 mg twice daily, n = 26* . | ||
| Deaths, no. (%) | 6 (21) | 4 (14) | 3 (11) | 3 (12) |
| Causes of death, no. | ||||
| Relapse of leukemia | 3 | 1 | 2 | 1 |
| Graft-versus-host-disease | 2 | 1 | 0 | 1 |
| Bacterial/fungal infection | 1 | 0 | 1 | 0 |
| Thrombotic thrombocytopenic purpura | 0 | 1 | 0 | 1 |
| Chemotherapy toxicity | 0 | 1 | 0 | 0 |
| . | Placebo, n = 28 . | Maribavir dose groups . | ||
|---|---|---|---|---|
| 100 mg twice daily, n = 28 . | 400 mg once daily, n = 28 . | 400 mg twice daily, n = 26* . | ||
| Deaths, no. (%) | 6 (21) | 4 (14) | 3 (11) | 3 (12) |
| Causes of death, no. | ||||
| Relapse of leukemia | 3 | 1 | 2 | 1 |
| Graft-versus-host-disease | 2 | 1 | 0 | 1 |
| Bacterial/fungal infection | 1 | 0 | 1 | 0 |
| Thrombotic thrombocytopenic purpura | 0 | 1 | 0 | 1 |
| Chemotherapy toxicity | 0 | 1 | 0 | 0 |
One patient randomized to maribavir 400 mg twice daily did not receive study drug and was excluded from the analysis.